Proposed Part D rule changes could be bane to brand drugmakers

Serebrov, Mari
January 2014
BioWorld Today;1/8/2014, Vol. 25 Issue 5, p1
The article discusses the U.S. Centers for Medicare & Medicaid Services' proposal of Part D rule change that would tip the formulary scale in favor of generics and biosimilars which is seen as a bane to pharmaceutical firms. The changes aims to remove the protection antidepressants and immunosuppresants have enjoyed under Part D. They would also offer coverage exceptions to encourage lower drug prices and control off-label use.


Related Articles

  • CMS Proposes Significant Changes to Medicare Part D Program's Administration. Earl, Jeremy; Goel, Arthur J.; Hance, Anne W.; McDonald, Kate; Michaels, Joel L. // Venulex Legal Summaries;2014Q1, p1 

    The article discusses the proposed changes of the U.S. Centers for Medicare & Medicaid Services (CMS) to key components of the Medicare Part D Program. The application of the non-interference provision to negotiations of pharmaceutical manufacturers with pharmacies and Part D Plan sponsors under...

  • Manufacturers Affected by Recent Medicare Part D Rule.  // Venulex Legal Summaries;2012 Q2, Special section p1 

    The article reports on the changes implemented by the U.S. Centers for Medicare & Medicaid Services (CMS) that impact the relationship between pharmaceutical manufacturers and the Medicare Part D Coverage Gap Discount program, as part of an omnibus Medicare Part C and Part D rulemaking. It...

  • Pharmacy groups on warpath over AMP. Paul, Reid // Drug Topics;7/23/2007, Vol. 151 Issue 14, p10 

    The article reports that the U.S. Centers for Medicare & Medicaid Services' (CMS) release of the final version of its average manufacturer price (AMP) rule has received universal disapproval from pharmacy organizations. The rule implements one of the elements of the Deficit Reduction Act of...

  • States divided over Medicaid AMP rule. Paul, Reid // Drug Topics;6/4/2007, Vol. 151 Issue 11, p24 

    The article reports that several U.S. states have already started to take action to prevent the impact of Centers for Medicare and Medicaid Services' final rule for implementation of average manufacturer price (AMP) for Medicaid reimbursement on generic drugs which is expected to take effect on...

  • Despite options, doughnut hole hurts seniors. Dearment, Alaric // Drug Store News;9/19/2011, Vol. 33 Issue 12, p22 

    The article focuses on the issues being faced by seniors on the Medicare Part D coverage gap during transition of the drug costs responsibilities to the patients. It says the issues arises as only 1-in-5 seniors were aware that the U.S. Centers for Medicare and Medicaid Services offers 50%...

  • Retail Rx Fights Medicaid 'Final' Rule. Toth, Wendy // SN: Supermarket News;7/16/2007, Vol. 55 Issue 29, p20 

    The article deals with the final Medicaid generic drug reimbursement formula released by the U.S. Centers for Medicare & Medicaid Services (CMS) in Baltimore, Maryland. The new formula will reimburse pharmacies an average of one-third below acquisition cost of these drugs, according to the...

  • Medicare Part D Audits Is your pharmacy prepared? Watkins, Angela // Drug Topics;Feb2011, Vol. 155 Issue 2, p30 

    The article discusses strategies for pharmacies in dealing with the audits of the Centers for Medicare & Medicaid Services (CMS) for the Medicare Part D program in the U.S. It outlines the field and desk audits of Medicare Part D plans and discloses the potential records to be assessed by the...

  • PHARMACY QUALITY ALLIANCE (PQA). Cranston, Laura // Chain Drug Review;1/7/2013, Vol. 35 Issue 1, p114 

    In this article, the author presents her views regarding the 2013 outlook for pharmaceutical industry in the U.S. She reflects on the role of the company Pharmacy Quality Alliance (PQA) in defining appropriate medication use. She appreciates a new Medicare Part D measure that is centered on...

  • Unleashing value: The changing payment landscape for the US pharmaceutical industry.  // Pharmaceutical Executive;Sep2012, Vol. 32 Issue 9, Special section p1 

    The article offers information on various forces which are redefining value for the pharmaceutical industry in the U.S. Most new biologics are much more expensive for patients than previously available drugs. The incentives offered by the U.S. Centers for Medicare and Medicaid Services (CMS) for...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics